{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cervical-cancer-hpv/diagnosis/differential-diagnosis/","result":{"pageContext":{"chapter":{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis","depth":2,"htmlHeader":"<!-- begin field ac5bf1f3-ce3a-40d6-8113-288b84d9c1da --><h2>What other causes of non-specific symptoms should I consider?</h2><!-- end field ac5bf1f3-ce3a-40d6-8113-288b84d9c1da -->","summary":"","htmlStringContent":"<!-- begin item 5db7b933-79b6-498f-82e9-8fcab26cb3e8 --><!-- begin field 0f1bfe08-85a8-4566-b42d-74f05d4401f4 --><ul><li>Other causes of non-specific symptoms include:<ul><li><strong>Sexually transmitted infections (STIs)</strong> — Cervicitis or pelvic inflammatory disease are most commonly caused by <em>Chlamydia trachomatis</em>, (and less commonly by <em>Gonorrhoeae neisseria) </em>and may present with vaginal discharge associated with post-coital or intermenstrual bleeding, dysuria, deep dyspareunia, or lower abdominal pain.<ul><li>Cervicitis is characterized by an inflamed cervix which bleeds easily and may be associated with a mucopurulent discharge.</li><li>Pelvic inflammatory disease is characterized by lower abdominal pain, with or without fever. Cervicitis may be seen, and adnexal tenderness and cervical excitation found on bimanual palpation.</li><li>For further information on the diagnosis, investigation, and management of STIs, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a>, <a class=\"topic-reference external-reference\" href=\"/topics/gonorrhoea/\">Gonorrhoea</a>, <a class=\"topic-reference external-reference\" href=\"/topics/pelvic-inflammatory-disease/\">Pelvic inflammatory disease</a> and <a class=\"topic-reference external-reference\" href=\"/topics/vaginal-discharge/\">Vaginal discharge</a>.</li></ul></li><li><strong>Endometrial cancer </strong>may present with postmenopausal bleeding.</li><li><strong>Endometriosis </strong>may present with pelvic pain, dysmenorrhoea, dyspareunia and abnormal bleeding. For more information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/endometriosis/\">Endometriosis</a>.</li><li><strong>An ectropion or cervical polyps </strong>may cause post-coital bleeding.</li><li><strong>Hormonal contraception </strong>may cause unscheduled bleeding, particularly when first prescribed.<ul><li>Unscheduled bleeding is common with all forms of hormonal contraception during the first 3 months of use. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/#unscheduled-bleeding\">unscheduled bleeding</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/management/combined-oral-contraceptive/#unscheduled-bleeding\">unscheduled bleeding</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.</li><li>Notable bleeding is also common in the first 6 months of use with the levonorgestrel intrauterine system (LNG-IUS) or progestogen-only implants. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/management/levonorgestrel-intrauterine-system/#starting-a-lng-ius\">unscheduled bleeding</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/\">Contraception - IUS/IUD</a>.</li></ul></li></ul></li><li>Always consider the need for a pregnancy test.</li></ul><!-- end field 0f1bfe08-85a8-4566-b42d-74f05d4401f4 --><!-- end item 5db7b933-79b6-498f-82e9-8fcab26cb3e8 -->","topic":{"id":"38328a3b-8997-55f8-afac-19e980523812","topicId":"e2dafa6e-4749-48b2-b981-fa906c90d627","topicName":"Cervical cancer and HPV","slug":"cervical-cancer-hpv","lastRevised":"Last revised in September 2020","chapters":[{"id":"417b3c03-a940-5eb6-8b35-698036862be5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b4186a4a-8c1e-51ad-9743-d00be5b18f3d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"c2a58da0-8965-5522-8b3d-618890f730d3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2a436c60-1809-5f9f-bf39-409fd07e7af5","slug":"changes","fullItemName":"Changes"},{"id":"6b2a8979-8ca9-5087-a80b-ea14445c034a","slug":"update","fullItemName":"Update"}]},{"id":"c207e9ef-e492-5e67-8986-8b48ff76c55f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"4e791e8f-015d-58bd-99ec-2689c4baa3e4","slug":"goals","fullItemName":"Goals"},{"id":"b04fb3a0-7363-5d87-b475-a7ad1e7ca9af","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"af911672-6dba-57d0-b3bf-4058c30f91ff","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"16911bc4-aa1d-56b2-aaf3-39695a5692f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9c781faa-cf3f-5dcc-b39d-4c10588cbbfb","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"713db7a4-b4c8-55f3-8ca0-e5c0db230466","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2f3819e7-a39a-5399-98a2-014b4d9243c2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e32e97af-cb99-5487-8ceb-1d8db9b2fe5f","slug":"types-of-cervical-cancer","fullItemName":"Types of cervical cancer"},{"id":"02013d86-5f8b-50e2-8bbc-9e9e5335f72d","slug":"causes","fullItemName":"Causes"},{"id":"961e80d0-b721-5756-b1df-56633ce9e5aa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4a62390f-59b9-5d3c-ad78-0394d8900138","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5f216154-2a06-5aee-9270-f2388b590979","slug":"prognosis","fullItemName":"Prognosis"},{"id":"98782e4e-b481-5526-803b-b5f18e566c5d","slug":"complications","fullItemName":"Complications"}]},{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0a170049-907b-518b-9506-127d186d0a96","slug":"clinical-features","fullItemName":"Clinical features"},{"id":"ae89986b-d468-50ca-b0d4-788dce1cc020","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"5aee8849-a5fc-592a-ba2f-161843f6a42e","slug":"cervical-cytology-sample","fullItemName":"Cervical cytology sample"},{"id":"8b13c601-cb6f-536e-a6cc-90001fa3357a","slug":"hpv-screening","fullItemName":"HPV screening"},{"id":"a05197b4-af3e-5fcb-9458-ec6446bb0cb9","slug":"referral","fullItemName":"Referral"}]},{"id":"75bee623-8a4b-5b31-b85b-b1f0cf45212d","fullItemName":"Management","slug":"management","subChapters":[{"id":"3918bf03-5c07-5c8f-bb28-5834e5dc1343","slug":"prevention","fullItemName":"Scenario: Prevention"},{"id":"5d0f88a0-5a31-5e1f-81ee-89cc202d9885","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"64ce0536-0d7d-554e-afc1-7859f158b82c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f4263e46-d3a8-5853-904f-7c0e9b926a1c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9b9af798-d073-5ea1-a174-157b46c68062","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e827e587-3f77-5c14-92f8-58f34c105bbe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"22b0924c-0e7d-5a46-b369-dd38ebbc4a39","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f012ac60-98ba-56b3-838a-7924e3544719","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"102ef6c4-0635-5f17-a33b-e2d83ec751b0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1f31eeae-6068-5e2c-8097-3666754f067e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0158af19-7ed5-56ac-a299-796dcf69f9a8","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"3a9d5997-de76-5d8c-8829-0c7e6340cb9e","slug":"basis-for-recommendation-97f","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 21fed462-97c5-41b8-8f8e-d31cffe15eb7 --><h3>Basis for recommendation</h3><!-- end field 21fed462-97c5-41b8-8f8e-d31cffe15eb7 -->","summary":null,"htmlStringContent":"<!-- begin item 97ffdeb5-71f9-4c25-9679-9a1919879153 --><!-- begin field c9196309-3d60-4a19-b9a4-773a4635540d --><p>This information is based on the Public Health England (PHE) guideline <em>Management and laboratory diagnosis of abnormal vaginal discharge: quick reference guide for primary care</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">PHE, 2013</a>], the Faculty of Sexual and Reproductive Healthcare guidelines <em>Management of vaginal discharge in non-genitourinary medicine settings</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">FSRH, 2012b</a>], and <em>Problematic bleeding with hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">FSRH, 2015</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SIGN, 2008</a>], Department of Health (DH) guideline <em>Clinical practice guidance for the assessment of young women aged 20-24 with abnormal vaginal bleeding</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">DH, 2010</a>], the British Medical Journal (BMJ) best practice guideline <em>Cervical cancer</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">BMJ, 2016</a>] and a systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">Shapley, 2006</a>].</p><h4>Excluding infection</h4><ul><li>DH guidelines recommend taking swabs for sexually transmitted infection, or referring to a genito-urinary medicine clinic all women 20–24 years of age with post-coital bleeding, and referring them to gynaecology or genito-urinary medicine if the bleeding persists for 6–8 weeks after treatment.</li><li>SIGN guidelines recommend testing all premenopausal women for <em>Chlamydia trachomatis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cervical-cancer-hpv/references/\">SIGN, 2008</a>].</li></ul><!-- end field c9196309-3d60-4a19-b9a4-773a4635540d --><!-- end item 97ffdeb5-71f9-4c25-9679-9a1919879153 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}